Compass is still being developed and is effectively in beta. Some content and features may be incomplete, change, or not work as expected.

Content is anchored to trusted sources where available, but Compass has not yet been clinically reviewed. It provides general information rather than medical advice.

Feedback helps us identify gaps, errors, usability problems and opportunities to improve Compass over time.

ALS Untangled does not recommend LEAP2BFIT for ALS

Original source

LEAP2BFITALSUntangled · 29 July 2020

ALS Untangled reviewed LEAP2BFIT and said it cannot currently recommend the product to slow, stop or reverse amyotrophic lateral sclerosis (ALS). Some ingredients may have potential benefits, but the product’s dosages are not disclosed and the combination has not been carefully tested.

Why this matters

People with ALS and their clinicians should not interpret this review as evidence that LEAP2BFIT changes the disease. The review says the effects of the full ingredient combination, whether positive or negative, are unknown.

Limitations and context

This is an independent expert review, not a clinical trial of LEAP2BFIT. The undisclosed dosages and lack of careful testing of the combination limit conclusions about its safety or effectiveness.

Relevant to you?